The Ethics of International Research with Abandoned Children by Millum, J.
21 DECEMBER 2007 VOL 318 SCIENCE www.sciencemag.org1874
T
he aim of human subjects research is to
create generalizable knowledge that
benefits future patients. Consequently,
it risks sacrificing the interests of research
participants for the greater good of society.
Ethics guidelines exist to minimize this risk.
Over the last decade, international biomedical
research in the context of substantial health-
care inequalities has focused discussion on
four ethical issues: (i) standards of care; (ii)
informed consent; (iii) ancillary care obliga-
tions; and (iv) posttrial benefits (see table,
right). It is appropriate to consider these issues
relative to the Bucharest Early Intervention
Project (BEIP) study (1), a randomized trial of
the effects of moving institutionalized young
children to foster care.
Four International Bioethical Issues 
The standard-of-care debate erupted in the
1990s around placebo-controlled trials in
developing countries of “short-course AZT”
for prevention of maternal-fetal HIV transmis-
sion. Short-course AZT was expected to be less
effective than the standard AZT treatment
available in developed countries. Critics argued
that using placebo controls, rather than stan-
dard treatment as an active control, constituted
a double standard—research forbidden on the
wealthy would be carried out on the poor (2, 3).
Supporters countered that it is permissible to
offer research participants in developing coun-
tries less-effective interventions than those
used in developed countries if doing so (i) is
scientifically necessary to answer an important
question; (ii) does not deny anyone treatment
they would otherwise receive; and (iii) is
intended to develop interventions that will
benefit the developing country (4).
Informed consent is fundamental to ethical
research. But some commentators argue that
valid informed consent cannot be obtained in
developing countries, whose inhabitants are
impoverished, poorly educated, deprived of
medical services, and unfamiliar with
research (5, 6). Others reply that this is patron-
izing and inaccurate. Poverty may constrain
choices, but it does not make people coerced
or incompetent, and participants in develop-
ing countries seem to understand the elements
of research as well, or badly, as their wealthier
counterparts (7). 
Ancillary care refers to medical treatments
provided by researchers during the trial above
and beyond what is required for safety or scien-
tific validity. Although researchers in develop-
ing countries often feel obliged to provide other
treatments that their subjects desperately need,
the nature and extent of these obligations are
not well defined. The most complete account
justifies ancillary care obligations because
research participants entrust aspects of their
health to investigators through the procedures
they undergo (8). 
Many believe that researchers have obliga-
tions to provide participants posttrial benefits.
These benefits are intended to prevent exploita-
tion, which occurs when one party takes unfair
advantage of another (9, 10). In international
research, the fear is that the developed world
will get too much of the benefits of medical
research and the developing world too much
of its burdens. According to the Council
for International Organizations of Medical
Sciences (CIOMS), research in a community is
permissible only if researchers or their spon-
sors ensure that interventions resulting from the
research are made “reasonably available” to the
community (11).  An alternative, the “fair ben-
efits” framework, proposes that posttrial bene-
fits may comprise a myriad of benefits includ-
ing ancillary care, training of health care
personnel, employment, and economic stimu-
lation, as well as the study intervention. The
total must be considered fair by the community
participating in the research (10).
The Ethics of the BEIP Study
The BEIP was a randomized trial comparing
institutional and foster care for abandoned
children currently in institutions. It took place
in Romania, where there are thousands of insti-
tutionalized children. Because, at the trial’s
inception, Romania lacked basic foster care,
the researchers developed their own, training
foster parents and providing social support. The
study found significantly improved cognitive
development at 42 and 54 months for children
transferred to foster care before 2 years of age
compared with institutionalized children.
The initial reaction to the BEIP may be that
the extreme vulnerability of abandoned, institu-
tionalized children renders any research on
them unethical. Not only are they unable to give
informed consent, there is no clear guardian
acting in their best interests. This puts them at
greater risk of being selected for reasons of
convenience rather than scientific necessity.
While these are valid concerns, familiar safe-
guards can protect such children. People who
cannot consent can be protected by enrolling
them only in minimal-risk research, whose
risks do not exceed those of everyday life. None
of the study’s assessments of functioning were
likely to harm the children. Restricting the par-
ticipation of vulnerable groups, such as prison-
ers and the institutionalized, to research that
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Standard of care Must interventions always be tested
against the treatment available in
developed countries?
Informed consent Can poor people in developing countries
give valid informed consent to research?
Ancillary care What treatments should be provided by
researchers during the trial beyond those
needed for safety or scientific validity?
Posttrial benefits What should be provided to research
participants and host communities after
the research trial?
Exceptions when scientifically necessary,
no harm, and research aims to benefit
community
Depends on the aspects of their health
that participants entrust to researchers
Two main approaches: reasonable
availability of study intervention and
fair benefits approved by the community
Available data do not show informed
consent is invalid
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addresses important questions relevant to their
situation protects against unfair subject selec-
tion (12). The BEIP study aimed to produce
results that would primarily benefit abandoned,
institutionalized children.
The BEIP has many of the features that
have generated special concern about medical
research in developing countries. Romania,
the host country, is a transition economy with
a relatively poor health-care infrastructure and
a large number of underserved institutional-
ized children. The funding and research lead-
ership for the trial came from the United
States. Although the results may be relevant to
the United States and other developed coun-
tries, there have been no American random-
ized trials comparing foster and institutional
care, and no American children would be
enrolled in the BEIP. Of greatest concern are
the standards of care affected in the trial arms
and the distribution of posttrial benefits.
The appropriate standard of care for a clini-
cal trial depends on the research question being
answered. Although the importance of equi-
poise, i.e., uncertainty among experts, is dis-
puted (13), ethics requires at least that the
research address an important question and be
scientifically valid. Trials that do not meet these
conditions lack social value. If a research study
will not generate socially useful knowledge, it
wastes resources and exposes participants to
risks and burdens for no good reason. 
The BEIP study addresses an important
question; the welfare of institutionalized chil-
dren depends on choosing correctly between
further institutional care or switching to foster
care. Prior data focused on adoption and did
not directly address this comparison, had
selection biases, and lacked a definitive ran-
domized trial. Thus, the study appears to ful-
fill equipoise. Moreover, although both insti-
tutional and foster care can sometimes result
in maltreatment, study participation was un-
likely to cause net harm to the children; no
child was put at additional risk to obtain the
results, which reduces the ethical reasons for
worrying about equipoise. 
Guarding Against Exploitation
To judge whether this trial involved exploita-
tion requires assessing whether the study’s
benefits were distributed fairly among the
parties involved. A useful framework is
national research. In a developed country, the
results of research are expected to eventually be
integrated, albeit haphazardly, into that coun-
try’s health system. Although participants
assume risks in research, they, and their fellow
citizens, also benefit. If all subject protection
requirements are fulfilled (14), the research is
permissible. But in international research, the
people that benefit may not come from the
same society as the research participants;
no shared national relationship between
researchers, subjects, and society exists. Thus,
outsourcing research may increase the potential
for exploitation.
One way to minimize the chance of
exploitation is to emulate national research.
According to CIOMS, achieving this in the
international context requires that the research
be responsive to the health needs of the study
population and that the population gains from
the research results (10, 11).
The BEIP meets these two conditions. The
research responds to the health needs of many
abandoned children for whom the state is
responsible. Moreover, the instigation of the
study by the Romanian Secretary of State for
Child Protection and official reaction to its
results indicate that the study had a high likeli-
hood of having an impact on these children’s
lives; state policy was likely to adopt the BEIP
conclusions. This impact is not guaranteed:
social and economic circumstances or govern-
ment policies might change, resources may not
be made available for foster care, or the conclu-
sions of the research may be disputed. Certainty
about implementation cannot be required to eth-
ically proceed with a study. Instead, researchers
must judge the likelihood that their work will
generate health benefits, and proceed on the
basis of its expected benefit. The expected
benefits to Romania’s abandoned children
appear to provide ample justification for the BEIP.
Finally, judging whether exploitation has
been avoided by using the responsiveness to
needs and reasonable availability criteria can
be problematic. These criteria consider bene-
fits to the participants’community. But it is the
participants—not the community—who bear
the risks of research and are therefore most
vulnerable to exploitation. Even when a suc-
cessful intervention will be available to a pop-
ulation after the trial’s completion, supplying it
to the research participants themselves may
not be possible.
Unfortunately, in many cases harm to par-
ticipants is inherent in generating valid scien-
tific results. In some trials, data on the effec-
tiveness of an intervention cannot be obtained
without some risk to the subjects, perhaps of
serious or fatal outcomes. For instance, for a
vaccine trial to be successful, some participants
must acquire the disease the vaccine is intended
to prevent. Otherwise, no intervention can be
shown to be superior. But the preventive bene-
fits of the vaccine do no good for participants
who became infected during the study. Similar
issues arise in many cancer and cardiovascular
trials. The BEIP raises the same concern; the
children who remained in institutional care
cannot now receive the benefit of early foster
care, which the trial showed to be superior for
some developmental outcomes. 
This consideration does not make the BEIP
study unethical, just as it does not make vaccine
trials unethical. However, it does indicate that
researchers need to pay special attention to how
results get implemented when the benefits can-
not accrue to participants. For instance, trial
designs that move participants into the arm that
is doing better during the course of the trial can
be employed. According to the researchers,
limited funds foreclosed this option. Alter-
natively, as done in the BEIP, researchers can
present valid scientific results as soon as possi-
ble to those parties who can act on them. These
parties have responsibilities to the participants,
too; because the children were involved in
research for the benefit of Romanian society,
the representatives of society should ensure that
the children get the care they deserve.
The BEIP researchers did not create and are
not responsible for Romania’s institutionaliza-
tion of abandoned children. They conducted
research to determine what interventions
would benefit these children. This is not ex-
ploitation, but shows how research can help
benefit participants, as well as the wider popu-
lation of abandoned institutionalized children.
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